El interés en corto de Guardant Health da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Guardant Health. Los datos de interés en corto se actualizan cada dos semanas.

Guardant Health (NASDAQ:GH) Bolsa, Informe de interés en corto

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Equities

News

Markets

ETFs

$BTC

ARKF

ARKG

ARKK

ARKW

COIN

EXAS

PLTR

PSNL

VRTX

El miércoles, Cathie Wood, a la cabeza de Ark Invest, realizó algunas operaciones significativas, siendo las más destacadas las de Coinbase Global Inc (NASDAQ:COIN) y Palantir Technologies Inc (NYSE:

Movimientos clave de Cathie Wood: ¿qué hay detrás de las últimas operaciones de Ark Invest?

Guardant Health Inc

HSBC BANK 30/10/26 WNT

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX, Inc. - Class A Common Stock

Gores Holdings IX Inc

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by GREENHEART GOLD INC.

GUARDION HLTH SCIENCS INC by Guardion Health Sciences, Inc.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

AMD GLOB HY ETF

GLJ Research analyst Gordon Johnson downgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Hold to Sell and announces $7.78 price target.

Downgrades

Price Target

Analyst Ratings

GLJ Research Downgrades Sunrun to Sell, Announces $7.78 Price Target

WIIM

IMVT

Immunovant shares are trading lower after the company reported worse-than-expected Q2 EPS results.

SEDG

Solar Edge shares are trading lower after the company announced worse-than-expected Q3 financial results.

Macquarie analyst Tim Nollen maintains LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) with a Outperform and maintains $43 price target.

RAMP

Macquarie Maintains Outperform on LiveRamp Holdings, Maintains $43 Price Target

Offerings

Fangdd Announces $5 Million Registered Direct Offering At $0.70 Per Share, Closing Expected November 8; Proceeds To Support General Corporate Purposes

Macquarie analyst Tim Nollen maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Outperform and raises the price target from $150 to $270.

Macquarie Maintains Outperform on AppLovin, Raises Price Target to $270

Macquarie analyst Tim Nollen maintains Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) with a Neutral and lowers the price target from $3 to $2.

APPS

Macquarie Maintains Neutral on Digital Turbine, Lowers Price Target to $2

Editor: The title of the story has been updated to reflect the amount of impairment charge.
SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) shares are trading lower after the company reported third-quarter results yesterday. Revenues were $260.9 million, <a href="https://www.benzinga.com//node/41786579">missing the consensus of $269.38 million.</a>
Revenues from the solar segment were&nbsp;$247.5 million, up&nbsp;3%&nbsp;from&nbsp;$241.2 million&nbsp;in the prior quarter and down&nbsp;63%&nbsp;from&nbsp;$676.9 million&nbsp;in the same period last year.
The company shipped&nbsp;850 Megawatts (AC) of inverters and 189 MWh of batteries for PV applications in the quarter.
Adjusted gross margin&nbsp;was negative 265.4% versus a&nbsp;positive margin of&nbsp;0.2%&nbsp;in the prior quarter and compared to&nbsp;20.8%&nbsp;last year.
Adjusted operating loss stood at&nbsp;$808.1&nbsp;million versus an adjusted operating loss of&nbsp;$114.3&nbsp;million&nbsp;last quarter.
Adjusted loss per share of&nbsp;$15.33&nbsp;may not be comparable to <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus loss of&nbsp;$1.63</a>.
Operating cash flow was negative&nbsp;$63.9&nbsp;million in the quarter. As of September 30, cash, cash equivalents, bank deposits, restricted bank deposits, and marketable securities&nbsp;totaled&nbsp;$53.3&nbsp;million.
In the third quarter, SolarEdge conducted an asset valuation review, which resulted in a $1.03 billion write-down and impairment of various assets.
Outlook: For&nbsp;the&nbsp;fourth quarter, the company expects revenue of&nbsp;$180&nbsp;million &#8211; $200 million (versus&nbsp;consensus of&nbsp;$308.66 million), revenues from the solar segment of&nbsp;$170&nbsp;million &#8211; $190 million, and adjusted gross <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">margin of&nbsp;negative&nbsp;4%&nbsp;&#8211;&nbsp;0%</a>.
Investors can gain exposure to the stock via&nbsp;Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>).
Price Action: SEDG shares were down 17.3% at $12.13 premarket at the time of writing on Thursday. The stock has recouped all losses and is up 0.31% to $14.73 at the time of update as of 14.15.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41799600" target="_blank" rel="noreferrer noopener">Nvidia Partners With AI Startup Hugging Face To Supercharge Open Source Robotics</a></li>
</ul>

Earnings

Large Cap

Guidance

Movers

SolarEdge's Tough Q3: Revenue Miss, $1 Billion Impairment Charge, Bleak Forecast & More (UPDATED)

<a href="https://www.youtube.com/watch?v=94uL1NRslpw">https://www.youtube.com/watch?v=94uL1NRslpw</a>
&nbsp;

Macro Economic Events

Global

Economics

Russia's Putin Congratulates Trump On Winning U.S. Presidential Elections; Says Desire To Restore Relations With Russia, Facilitate End Of Ukrainian Crisis Deserves Attention; Don't Think It's Wrong To Hold Call With Trump; If Some World's Leaders Seek To Restore Contacts, I'm Not Against It; We Are Ready To Speak To Trump

BTIG analyst Marvin Fong maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Buy and lowers the price target from $2250 to $2200.

MELI

BTIG Maintains Buy on MercadoLibre, Lowers Price Target to $2200

Deep-pocketed investors have adopted a bearish approach towards Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Sweetgreen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $250,030, and 6 are calls, amounting to $262,457.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $45.0 for Sweetgreen over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Sweetgreen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Sweetgreen's whale activity within a strike price range from $40.0 to $45.0 in the last 30 days. 
<h3>Sweetgreen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731007036_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.3</td>
<td>$3.0</td>
<td>$3.29</td>
<td>$41.00</td>
<td>$163.1K</td>
<td>83</td>
<td>512</td>
</tr>
<tr>
<td>SG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.9</td>
<td>$2.75</td>
<td>$2.89</td>
<td>$40.00</td>
<td>$86.8K</td>
<td>2.2K</td>
<td>321</td>
</tr>
<tr>
<td>SG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.16</td>
<td>$41.00</td>
<td>$61.7K</td>
<td>390</td>
<td>3.2K</td>
</tr>
<tr>
<td>SG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.3</td>
<td>$41.00</td>
<td>$49.3K</td>
<td>390</td>
<td>2.9K</td>
</tr>
<tr>
<td>SG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$11.9</td>
<td>$11.6</td>
<td>$11.85</td>
<td>$40.00</td>
<td>$41.4K</td>
<td>301</td>
<td>35</td>
</tr>
</tbody>
</table>

<h3>About Sweetgreen</h3>
Sweetgreen Inc is a next-generation restaurant and lifestyle brand that serves healthy food at scale. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
In light of the recent options history for Sweetgreen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Sweetgreen</h3>
<ul>
<li>With a volume of 3,351,690, the price of SG is up 1.15% at $42.12. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Sweetgreen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Decoding Sweetgreen's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bullish approach towards Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TOST usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Toast. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 80% leaning bullish and 10% bearish. Among these notable options, 3 are puts, totaling $139,066, and 7 are calls, amounting to $316,468.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $28.0 to $45.0 for Toast during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Toast's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Toast's whale trades within a strike price range from $28.0 to $45.0 in the last 30 days. 
<h3>Toast Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731007031_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.65</td>
<td>$12.55</td>
<td>$12.55</td>
<td>$45.00</td>
<td>$79.0K</td>
<td>0</td>
<td>63</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.04</td>
<td>$2.0</td>
<td>$2.03</td>
<td>$35.00</td>
<td>$61.0K</td>
<td>3.8K</td>
<td>721</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.83</td>
<td>$0.77</td>
<td>$0.83</td>
<td>$36.00</td>
<td>$55.2K</td>
<td>83</td>
<td>3.7K</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$5.25</td>
<td>$4.85</td>
<td>$5.06</td>
<td>$28.00</td>
<td>$50.5K</td>
<td>131</td>
<td>172</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$31.00</td>
<td>$44.5K</td>
<td>152</td>
<td>146</td>
</tr>
</tbody>
</table>

<h3>About Toast</h3>
Toast is a us-based restaurant technology company that provides point-of-sale, payment processing, and various software services to 120,000 restaurant locations across the United States at the end of June 2024. The firm generates sales from software subscription fees, as a percentage take rate from each financial transaction it processes, from loan origination and servicing fees from its Toast Capital arm, and from hardware installation and professional services. Unlike competitors, Toast intermediates every payment transaction on its platform, processing some $126 billion in gross platform volume in 2023. The firm's product offerings span point-of-sale systems, inventory and payroll management, delivery integration, e-commerce ordering, reservation management, and loyalty programs.
<h3>Current Position of Toast</h3>
<ul>
<li>With a trading volume of 7,268,146, the price of TOST is up by 1.24%, reaching $32.54.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Toast</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $31.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stephens &amp; Co. persists with their Equal-Weight rating on Toast, maintaining a target price of $30. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Toast, targeting a price of $33. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Toast, maintaining a target price of $33. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Toast, targeting a price of $30. 
&#x2A; An analyst from Deutsche Bank has decided to maintain their Hold rating on Toast, which currently sits at a price target of $30. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Toast with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

TOST

Looking At Toast's Recent Unusual Options Activity

Craig-Hallum analyst Jeremy Hamblin maintains Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) with a Buy and raises the price target from $85 to $120.

KRUS

Craig-Hallum Maintains Buy on Kura Sushi USA, Raises Price Target to $120

Barrington Research analyst Alexander Paris maintains Strategic Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) with a Outperform and maintains $135 price target.

STRA

Barrington Research Maintains Outperform on Strategic Education, Maintains $135 Price Target

BTIG analyst Marvin Fong maintains Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Buy and raises the price target from $14 to $16.

UPWK

BTIG Maintains Buy on Upwork, Raises Price Target to $16

Craig-Hallum analyst Jeff Van Rhee maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and raises the price target from $23 to $24.

CLBT

Craig-Hallum Maintains Buy on Cellebrite DI, Raises Price Target to $24

BTIG analyst Clark Lampen maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $202 to $291.

BTIG Maintains Buy on AppLovin, Raises Price Target to $291

Albemarle shares are trading higher. The company reported Q3 financial results.

Zillow Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) shares are trading higher. <a href="https://www.benzinga.com/news/earnings/24/11/41791923/zillow-stock-jumps-on-q3-earnings-revenue-beat-eps-beat-visits-up-3-233m-monthly-active-users">The company reported earnings and investors positively reacted. </a>Estimates for the earnings were 29 cents and came in at 35 cents. Revenue was $581 million versus estimates of $555 million.
Our team of technical analysts made Zillow our Stock of the Day because it illustrates a common dynamic in the market that savvy traders use to profit.
As you can see on the chart, in February and early March levels around $58.50 were resistance for the stock. In September this resistance was broken. Then the stock eventually fell back to the $58.50 level that was previously resistance converted into support.
The same thing happened at the $53.70 level. It was resistance in July and converted to support at the beginning of September.
At the end of September, the $68.40 level was resistance — and now it has become a support level.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-1024x524.png" alt="" class="wp-image-636121" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-1536x786.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024.png 1585w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814670/donald-trumps-win-coupled-with-macro-factors-sets-stage-for-accelerated-cycle-in-crypto-ma">Donald Trump&#8217;s Win Coupled With Macro Factors Sets Stage For &#8216;Accelerated Cycle&#8217; In Crypto Markets, Analyst Predicts</a>
Price levels resistant converting into support is a common occurrence in not just the stock markets, but in all financial markets.
It happens because of &#8220;seller's remorse.&#8221;
There are investors and traders who sell while the stock is at resistance who think they made a good decision if the price trends lower after. But if the trend reverses, the resistance is broken and the price moves higher, many who sold come to regret their decision to do so.
Some of these remorseful sellers vow to buy their shares back.
But they will only do so if they can buy them for the same price they were sold. So as a result, if the stock eventually falls back to the selling price they place buy orders.
If there are enough of these orders it will cause support to form at the price that had previously been resistance.
If a stock is trending lower and a trader is looking for insight into where to buy it, they should look at price levels that had previously been resistance. There is a good chance the stock finds support at them. They may even reverse and rally.
Read Next: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a>
Photo: Shutterstock

Technicals

Trading Ideas

Real Estate

Stock Of The Day: Why Would Resistance For Zillow Turn Into Support?

Starting in 2025, students at the California Institute of Integral Studies (CIIS) in San Francisco will be able to pursue a unique academic path: a bachelor's degree in psychedelics studies. This marks the first time an accredited institution in the United States has offered an undergraduate degree focused on <a href="https://www.benzinga.com/markets/psychedelics">hallucinogenic drugs</a>. As The San Francisco Standard <a href="https://sfstandard.com/2024/11/06/psychedelic-major-degree-undergraduate-ciis/">reported</a>, the program aims to prepare students for careers in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic therapy</a>, integrating psychology, anthropology and neuroscience to explore psychedelics&#8217; role in therapy and society.
Nick Walker, a psychology professor at CIIS who helped design the curriculum, described the program as the result of years of development. "We have incorporated psychology, cultural anthropology, neuroscience, a lot of different angles," Walker explained. One module explores the history of hallucinogens, including <a href="https://www.benzinga.com/markets/cannabis/23/04/31704770/exclusive-the-importance-of-attaining-a-decolonized-perspective-of-psychedelics-therapy">colonialism&#8217;s impact</a> on psychedelics tourism, reflecting the program&#8217;s interdisciplinary approach. CIIS aims to give students a broader, more nuanced understanding of psychedelics beyond recreation.
<h3 class="wp-block-heading">A Response To Growing Demand In Psychedelic Therapy</h3>
The new degree comes amid a <a href="https://www.benzinga.com/markets/cannabis/24/11/41761516/americans-favor-psilocybin-for-mental-health-treatment-study-finds">broader wave of interest in psychedelic therapies</a>, which have shown promise in treating conditions like depression, PTSD and addiction. As <a href="https://www.benzinga.com/topic/psychedelics-research">researchers continue to publish promising results</a>, the market for psychedelic therapies is <a href="https://www.benzinga.com/markets/cannabis/24/10/41589487/global-psychedelic-drugs-market-expected-to-reach-10-2b-by-2028-amid-growing-mental-health-crise">expected to exceed $4.6 billion by 2030</a>, driving a need for professionals trained in the therapeutic application of these substances.
Until now, CIIS and other universities like Berkeley and Columbia have <a href="https://www.benzinga.com/markets/cannabis/24/02/37394447/beckley-academys-open-source-psychedelic-therapy-learning-framework-is-out-whats-it-all-about-au">offered certification programs</a>, but these have been limited to medical professionals and licensed therapists. This new undergraduate program, however, will introduce students to psychedelic studies without the need for previous clinical experience.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41814007/pro-golfers-turn-to-psychedelics-for-focus-boost-and-anxiety-relief">Pro Golfers Turn To Psychedelics For Focus Boost And Anxiety Relief</a>
<h3 class="wp-block-heading">Ethics And Boundaries In Psychedelic Studies</h3>
Ethical considerations are central to CIIS's approach. The curriculum includes immersive experiences and role-playing to help students understand altered states without direct drug use. "This is the first Bachelor of Science in psychedelic studies. That's what the diplomas will say," Walker said. However, he emphasized that the degree is not a professional training program in psychedelic therapy. "If they want to be a psychedelic-assisted therapist, they're going to have to go to grad school and get licensed."
Following past controversies, CIIS has strengthened ethical standards. After a 2021 <a href="https://www.thecut.com/2021/11/cover-story-podcast-goes-into-world-of-psychedelic-therapy.html">podcast</a> exposed alleged misconduct by instructors in psychedelic-assisted therapy, CIIS terminated their contracts and now requires faculty and students to sign an integrity agreement prohibiting romantic relationships with clients. While the scandal wasn&#8217;t directly addressed at the program&#8217;s launch, the importance of consent in therapy was emphasized.&nbsp;
"Touch in psychedelic psychotherapy is really cutting edge, but it's high risk, high reward," said CIIS psychology professor Jason Butler, a panelist at the launch event and <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine-assisted therapy</a> specialist. "A number of ethical violations have surfaced. … We need to talk about consent before any psychedelic medicine is ingested."
<h3 class="wp-block-heading">Expanding Offerings in Psychedelic Therapy Training</h3>
The new CIIS degree program is not the only new development on the horizon. In 2025, the institute will also launch a ketamine-assisted therapy clinic staffed by graduate students who are licensed clinicians. The clinic will offer supervised experience in ketamine-assisted psychotherapy, a booming treatment in mental health care.
As Walker summarized, "Whatever our graduates end up doing, we hope they'll bring with them high levels of understanding, cultural humility, intellectual curiosity, critical thinking, and ethical integrity."
Cover image made with AI

Cannabis

Psychedelics

Education

California College Launches Nation's First Psychedelic Studies Degree For Undergraduates

Guardant Health surges 15% on boosted revenue guidance range, Q3 beats

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – AppLovin (APP)&nbsp;up 28.6% ...

Closing Bell Movers: AppLoving up 29% after Q3 earnings beat

Guardant Health, Inc. 2024 Q3 - Results - Earnings Call Presentation

Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript

Guardant Health ( ($GH) ) has released its Q3 earnings. Here is a breakdown of the information Guardant Health presented to its investors. Guardant...

Guardant Health Boosts 2024 Revenue Outlook

TD Cowen analyst Daniel Brennan maintained a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $42.00. Danie...

Guardant Health: Strong Financial Performance and Growth Prospects Lead to Buy Rating

Analyst Mark Massaro of BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), retaining the price target of $50.00. Mark Massaro ...

Guardant Health: Strong Financial Performance and Strategic Growth Potential Earns Buy Rating

Aristotle Large Cap Growth Q3 2024 Commentary

Aristotle Core Equity Q3 2024 Commentary

In a report released today, William Bonello from Craig-Hallum reiterated a Buy rating on Guardant Health (GH – Research Report), with a price targe...

Craig-Hallum Remains a Buy on Guardant Health (GH)

ACLS

ADPT

AMAT

ASPN

BMRN

BROS

CPRX

CTVA

DUOL

DXCM

EXPE

FRSH

GILD

GOOG

HUBS

IDXX

KLAC

MKSI

MTCH

QCOM

RRGB

RXRX

SNPS

SRPT

TNDM

TRIP

TSLA

TTWO

WOLF

Press Releases

Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long

Comments

Guardant Health

Interés en corto

Guardant Health (NASDAQ:GH) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL